| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Subodh Verma | |
| Paul E Szmitko | |||
| Lawrence A Leiter | |||
| P2860 | cites work | Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 |
| Stimulation of insulin secretion by gastric inhibitory polypeptide in man | Q69602585 | ||
| Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity | Q70239999 | ||
| PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION | Q77059466 | ||
| Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 | Q77804907 | ||
| Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures | Q78570627 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Finding new treatments for diabetes--how many, how fast... how good? | Q79701190 | ||
| Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells | Q80217129 | ||
| Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes | Q80349827 | ||
| Modulation of hematopoietic stem cell homing and engraftment by CD26 | Q80450248 | ||
| Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride | Q80825411 | ||
| Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting | Q80843544 | ||
| Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials | Q94680556 | ||
| A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 | ||
| Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line | Q24609542 | ||
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 | ||
| Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV | Q28188612 | ||
| New Markers of Inflammation and Endothelial Cell Activation | Q28211342 | ||
| Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain | Q28256443 | ||
| Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes | Q28260260 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice | Q28510783 | ||
| Effect of GIP and GLP-1 antagonists on insulin release in the rat | Q28566429 | ||
| Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | Q28571689 | ||
| Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats | Q28574165 | ||
| Cardiac function in mice lacking the glucagon-like peptide-1 receptor | Q28586718 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| The failing heart--an engine out of fuel | Q29617881 | ||
| Circulating CD26 is negatively associated with inflammation in human and experimental arthritis | Q31144845 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas | Q34234727 | ||
| Adipokines: molecular links between obesity and atheroslcerosis | Q34384883 | ||
| Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis | Q34530843 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| International Union of Pharmacology. XXXV. The glucagon receptor family | Q35077448 | ||
| Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance | Q35144434 | ||
| Identification and Actions of Gastric Inhibitory Polypeptide | Q35155165 | ||
| Endothelial progenitor cells: new hope for a broken heart | Q35160551 | ||
| Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. | Q35189265 | ||
| The role of gut hormones in glucose homeostasis | Q35251016 | ||
| Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. | Q35809679 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. | Q36075992 | ||
| Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus | Q36693199 | ||
| Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action | Q36751470 | ||
| Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons | Q37351161 | ||
| Inhibition of gastric inhibitory polypeptide signaling prevents obesity | Q38288099 | ||
| Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. | Q38301976 | ||
| Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes | Q38323148 | ||
| Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow | Q40437409 | ||
| Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells | Q40710884 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes | Q42165729 | ||
| Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients | Q42485797 | ||
| The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects | Q42495611 | ||
| Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). | Q42574446 | ||
| Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes | Q42824310 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers | Q43913912 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia | Q44031294 | ||
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects | Q44081118 | ||
| Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells | Q44241973 | ||
| Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects | Q44273278 | ||
| Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets | Q44320631 | ||
| Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). | Q44333619 | ||
| Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia | Q44452284 | ||
| Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes | Q44467078 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. | Q44936558 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. | Q45257473 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus | Q46466735 | ||
| Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy | Q46604606 | ||
| Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice | Q46734172 | ||
| Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 | ||
| Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. | Q46849874 | ||
| Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans | Q46919674 | ||
| Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts | Q46952887 | ||
| Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey | Q46966712 | ||
| Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. | Q47273005 | ||
| Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes | Q47317632 | ||
| Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action | Q47744392 | ||
| The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. | Q51473976 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. | Q51478128 | ||
| Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. | Q51479779 | ||
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. | Q51492143 | ||
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. | Q51552912 | ||
| Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. | Q51584065 | ||
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
| Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. | Q52522147 | ||
| Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. | Q52951285 | ||
| Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. | Q53624218 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain | Q56700830 | ||
| U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 | ||
| Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
| Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats | Q59616311 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 87-95 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | The Canadian Journal of Cardiology | Q3502278 |
| P1476 | title | The incretin system and cardiometabolic disease | |
| P478 | volume | 26 |
Search more.